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AJH 2005; 18:1313–1319Background: Most treated hypertensive patients do not
achieve adequate blood pressure (BP) control. Initiating ther-
apy with two drugs has been suggested when BP is 20/10
mm Hg above goal. To ensure patients’ compliance, such
treatment needs to be well tolerated and must not compro-
mise health-related quality of life (HRQL). The primary
objective of this study was to compare the effects on HRQL
of initiating treatment with felodipine  metoprolol (FM)
fixed combination tablets, or enalapril (E), or placebo (P).
Methods: A total of 947 patients of both sexes with
primary hypertension (diastolic BP 95 to 110 mm Hg),
aged 20 to 70 years, participated in this randomized,
double-blind, parallel group, 12-week, multicenter trial.
Treatment was initiated with FM 5  50 mg, or E 10
mg, or P. Doses were doubled after 4 or 8 weeks if
diastolic BP was 90 mm Hg. The HRQL was measured
at baseline and at the last visit using two validated ques-
tionnaires: the Psychological General Well-being Index
Nylands kretssjukhus (C-JL), Ekenäs, Finland; Institut for hypertoniker,
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Published by Elsevier Inc.(PGWB) and the Subjective Symptom Assessment Profile
(SSA-P). Office BP was measured at trough, that is, 24 h
after the previous dose.
Results: The HRQL was high at baseline and generally
well maintained during the study. For example, the mean
(SD) PGWB total score was 104 (16) at baseline and 105 (16)
at 12 weeks in all three treatment groups. The BP reductions
after FM (18/14 mm Hg) and E (12/9 mm Hg) were
significantly greater than after P (7/7 mm Hg), and the re-
duction after FM was significantly greater than after E.
Conclusions: The HRQL is maintained in the pres-
ence of substantial BP reduction during antihypertensive
treatment with FM fixed combination tablets. Am J
Hypertens 2005;18:1313–1319 © 2005 American Journal
of Hypertension, Ltd.
Key Words: Enalapril, felodipine, health-related qual-
ity of life, hypertension, metoprolol.A ntihypertensive drug therapy reduces cardiovas-cular morbidity and mortality.1–3 However, manytreated hypertensive patients remain at increased
cardiovascular risk because of insufficient blood pressure
(BP) reduction. In the US it was recently shown that the
recommended target BP (140/90 mm Hg or less) was only
achieved in 30% of treated Americans.3 This suboptimal
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generally an asymptomatic condition, whereas antihypertensive
drug therapy may elicit adverse drug reactions and compromise
the patient’s health-related quality of life (HRQL).5,6 Such pos-
sible drawbacks of drug therapy will negatively affect the doc-
tor’s willingness to prescribe effective treatment, and also impair
the patient’s compliance. Many doctors and patients fear that the
substantial BP reductions needed to achieve the recommended
BP target, and the drug combinations necessary to reach this
goal, may affect HRQL negatively.
Thus, for best possible prevention of cardiovascular
complications, antihypertensive drug regimens need to be
both effective and well tolerated, and must not compro-
mise the patients’ HRQL. Combinations of drugs with
complementary mechanisms of action may be particularly
useful in this context, as they can provide improved BP
reduction with maintained tolerability and HRQL, and
current guidelines on the management of hypertension do
recommend fixed combinations.3,4 The American guide-
lines suggest consideration should be given to initiating
therapy with two drugs, either as separate prescriptions or
in fixed dose combinations when BP is more than 20/10
mm Hg above goal.3
Controlled release combination tablets containing felodip-
ine, a vascular selective dihydropyridine calcium antagonist,
and metoprolol succinate, a 1-selective adrenoceptor antag-
onist, reduce the BP more effectively than any of its compo-
nents, without compromising tolerability.7 The effect of
felodipine  metoprolol combination tablets on HRQL in
hypertensive patients has so far not been specifically stud-
ied.
The rationale behind this placebo-controlled study was
the assumption that felodipine  metoprolol combination
tablets reduce BP substantially in patients with primary
hypertension without compromising HRQL. It was decided
to compare felodipine  metoprolol not only with placebo,
but also with a commonly used, effective, and well-tolerated
monotherapy. This comparison could indicate whether the
combination would be a possible alternative for initiating
treatment. The primary objective was to compare the ef-
fects of the three treatments (felodipine  metoprolol,
enalapril, or placebo) on HRQL. Other objectives were to
compare the BP-lowering effects and tolerability (adverse
events). This article presents the HRQL part of the study
together with brief data on BP. Detailed results on BP and
tolerability have been published previously.8
Methods
Study Population
Men and women, aged 20 to 70 years, with primary
hypertension and sitting diastolic BP 95 to 110 mm Hg
after a 4-week single-blind, run-in period with placebo
treatment, were eligible for inclusion in the study. A
further inclusion criterion was that patients should be able
to understand and complete the HRQL questionnaires.
Patients with known intolerance to any of the study drugswere excluded, as were patients with a history of recent
psychiatric or cardiovascular disease, insulin-treated dia-
betes, impaired liver function, renal artery stenosis, or any
condition associated with poor compliance. A total of 947
patients from 96 study sites (mostly general practices) in
12 countries were randomized: Austria (n  34), Belgium
(n  118), Canada (n  90), Finland (n  40), France
(n  106), Greece (n  56), Norway (n  82), Poland (n
 70), Spain (n  69), Sweden (n  110), Switzerland (n
 47), and UK (n  125). Before inclusion all patients
gave written informed consent in accordance with the
Helsinki declaration. The study was conducted according
to Good Clinical Practice and was approved by all local
Ethics Committees.
Study Design and Conduct
This was a randomized, placebo-controlled, double-blind,
parallel group study. Eligible patients were randomized to 12
weeks of double-blind treatment with either felodipine 
metoprolol, enalapril, or placebo. All treatments were given
once daily. The initial dosage of felodipinemetoprolol was
5 50 mg and that of enalapril was 10 mg. The doses were
doubled to a maximum of 10  100 mg and 20 mg, and
corresponding placebo, at check-up visits after 4 or 8
weeks of treatment if sitting diastolic BP was not90 mm
Hg. The doses were also doubled if, at any time after
randomization, BP was 180 mm Hg systolic or 105
mm Hg diastolic. If the BP remained at this high level after
7 d, the patient was discontinued from the study.
Health-Related
Quality of Life Assessments
The patients answered two validated, self-administered
HRQL questionnaires at randomization and after 12 weeks
of double-blind treatment to assess both general well-
being and specific subjective symptoms. The question-
naires were also used at study enrolment (ie, before
randomization) to familiarize the patients with the proce-
dures. The patients answered the questionnaires during the
clinic visit before any other measurements or examina-
tions were made. To promote quality and avoid missing
values, the questionnaires were checked for completeness
before the patient left the clinic.
General well-being was evaluated using the Psycholog-
ical General Well-Being (PGWB) Index.9 This question-
naire measures subjective well-being or distress, and is
well-documented in terms of reliability and validity.10,11 It
contains 22 items that, apart from giving a total score,
combine into six dimensions: anxiety, depressed mood,
positive well-being, self-control, general health, and vital-
ity. The patient rates each item on a six-point scale (with
6 as the most positive option and 1 as the most negative).
The PGWB total score gives a maximum of 132 and a
minimum of 22.
Subjective symptoms were evaluated using the vali-
dated Subjective Symptom Assessment Profile (SSA-P).12
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monly reported among treated and untreated hypertensive
patients. It contains 42 symptoms (items). A visual analog
scale is used to rate each item (ie, a 100-mm straight line
with its end-points defined in words denoting the extreme
poles). Highly correlated items are categorized into six
dimensions: emotional distress (7 items), gastrointestinal
symptoms (6 items), peripheral vascular symptoms (5
items), cardiac symptoms (3 items), sex life (2 items), and
dizziness (2 items). The remaining 17 items are presented
as single items. The scale ranges from 0 to 100. A low
value indicates few or less pronounced symptoms,
whereas a high score indicate severe symptoms, or poor
functioning.
BP Measurements
At all clinical visits, BP was measured 24 h after the last
intake of study medication. Blood pressure was measured
after 5 min of rest in the seated position, and always in the
same arm, using a mercury sphygmomanometer and a cuff
size appropriate to the patient’s arm. The measurements
were made in duplicate and the mean was calculated and
used in all analyses.
Statistical Analysis
The study was analyzed using the intention-to-treat ap-
proach. Changes in HRQL variables and BP, from base-
line to the last visit (12 weeks), were compared between
treatments using a two-way analysis of variance model
with treatment and country as factors. Country rather than
center was used in the model because of the large number
of centers, some of which had only a few patients.
The change in PGWB total score was the primary
efficacy variable. Using Bonferroni’s method to adjust for
multiple tests, a P value less than .017 was considered
significant. Accordingly, the 98.3% confidence intervals
(CI) for the true mean differences between treatments are
Table 1. Demographics, clinical data, and medical
Placeb
(n  30
Male/female (n) 169/13
Age (yr) 51.0 (10
Seated DBP (mm Hg) 101.0 (4.4
Seated SBP (mm Hg) 157.2 (15
History of
Myocardial infarction (n) 6 (2.0
Cerebrovascular disease (n) 5 (1.6
Diabetes mellitus (n) 10 (3.3
Obstructive pulmonary disease (n) 6 (2.0
Renal disease (n) 7 (2.3
Liver disorder (n) 13 (4.3
Allergy (n) 38 (12
Means (SD) where applicable.given in the results. Two hundred patients per treatmentgroup were required to demonstrate a difference in change
in PGWB total score of 3.5 or more between any two
treatments, with an  error of 5% and 80% power, assum-
ing a standard deviation of 12.5.
Results
A total of 947 patients were randomly allocated to treat-
ment with felodipine  metoprolol (n  321), or enalapril
(n 321), or placebo (n 305). The baseline demograph-
ics, BP, and medical history in the three treatment groups
are given in Table 1. The patient flow is shown in Fig. 1.
One hundred two patients discontinued the study prema-
turely (40 due to adverse events, 45 because of too high
BP, and 17 due to other reasons. One randomized patient
who received two different sets of blinded medication
(intended for different patients) was excluded from the
ory at baseline
Enalapril
(n  321)
Felodipine-Metoprolol
(n  321)
188/133 177/144
52.4 (10.2) 51.5 (10.8)
100.9 (4.6) 101.1 (4.3)
158.0 (15.4) 157.6 (15.3)
7 (2.2%) 3 (0.9%)
2 (0.1%) 5 (1.6%)
21 (6.5%) 12 (3.7%)
3 (0.9%) 3 (0.9%)
17 (5.3%) 16 (5.0%)
6 (1.9%) 11 (3.4%)
) 36 (11.2%) 26 (8.1%)hist
o
4)
5
.7)
)
.3)
%)
%)
%)
%)
%)
%)
.5%FIG. 1. Flow chart of patients. Numbers of patients randomized,
discontinued, and followed for 12 weeks (end of study).
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analysis.
Health-Related Quality of Life
General Well-Being The mean PGWB scores at baseline
and the 12-week visit in the treatment groups, and the mean
changes from baseline, are given in Table 2. The table also
shows the 98.3% CI for the between-group comparisons. The
mean PGWB total scores were similar and relatively high in
all three treatment groups at baseline, and remained fairly
constant during the study. The same applied to all PGWB
dimensions. In fact, there was no change or a slight nu-
merical increase in all scores in all treatment groups (ie,
the general well-being was not compromised by any of the
treatments, and there were no treatment differences).
Subjective Symptoms The mean scores in the SSA-P
dimensions at baseline and the 12-week visit in the treat-
ment groups, and the mean changes from baseline, are
given in Table 3. The table also shows the 98.3% CI for
the between-group comparisons. The mean scores were
similar and relatively low at baseline in all three treatment
groups, and the mean changes during the study were
generally small. However, there was a slight increase in
Table 2. The Psychological General Well-Being Ind
n
Baseline 12-
Mean SD Mean
Total score
Placebo 249 103.6 15.4 104.8
Enalapril 289 104.3 16.6 105.5
Felodipine–Metoprolol 297 104.3 16.3 105.5
Anxiety
Placebo 249 23.5 4.4 23.9
Enalapril 288 23.8 4.5 24.4
Felodipine–Metoprolol 297 23.8 4.7 24.2
Depressed mood
Placebo 249 15.9 2.4 15.9
Enalapril 289 16.0 2.4 16.0
Felodipine–Metoprolol 296 15.8 2.5 15.8
Positive well-being
Placebo 249 16.6 3.3 16.7
Enalapril 288 16.8 3.7 16.9
Felodipine–Metoprolol 296 16.7 3.6 16.9
General health
Placebo 249 14.6 2.7 14.9
Enalapril 289 14.5 2.7 14.8
Felodipine–Metoprolol 297 14.8 2.6 14.9
Self Control
Placebo 249 15.5 2.2 15.7
Enalapril 289 15.5 2.5 15.5
Felodipine–Metoprolol 297 15.4 2.5 15.6
Vitality
Placebo 248 17.6 3.7 17.7
Enalapril 289 17.8 3.7 17.9
Felodipine–Metoprolol 297 17.8 3.6 18.1the gastrointestinal symptoms score during treatment withfelodipine  metoprolol (mean 1.8), which differed sig-
nificantly from the slight decreases recorded during treat-
ment with enalapril (mean 1.4) or placebo (mean 2.0).
The mean scores in SSA-P single items were relatively
low and similar in the three treatment groups and at
baseline. The mean changes from baseline to the 12-week
visit were generally modest, with two exceptions; the
score for swollen ankles increased by 8.9 (from 12.5)
during treatment with felodipine  metoprolol, and the
score for dry cough increased by 8.3 (from 17.0) during
treatment with enalapril. However, these symptoms were
mild or moderate in the majority of patients and caused
few discontinuations. Five patients discontinued due to
swollen ankles in the felodipine  metoprolol group, and
only one patient discontinued due to cough in the enalapril
group.
Antihypertensive Effect
A lower proportion of patients treated with felodipine 
metoprolol (38%) required a dose increase compared to
those treated with enalapril (61%) or placebo (73%). The
mean reductions in sitting BP from baseline to the 12-
week visit were 18/14 mm Hg (systolic BP/diastolic BP)
the higher the score the higher the well-being)
k
Difference
12-week 
Baseline
Comparison 98.3% CISD Mean SD
6.0 1.2 14.3 PI-FM 2.349; 2.815
5.6 1.2 11.4 PI-E 2.520; 2.672
6.2 1.2 12.0 E-FM 2.321; 2.636
4.6 0.5 4.4 PI-FM 0.699; 0.928
4.1 0.6 3.7 PI-E 0.919; 0.719
4.5 0.4 3.8 E-FM 0.567; 0.996
2.4 0.0 2.4 PI-FM 0.453; 0.421
2.4 0.0 2.0 PI-E 0.460; 0.418
2.4 0.0 2.0 E-FM 0.415; 0.424
3.6 0.1 3.1 PI-FM 0.630; 0.536
3.6 0.1 2.7 PI-E 0.529; 0.643
3.7 0.2 2.7 E-FM 0.664; 0.456
2.4 0.4 2.5 PI-FM 0.174; 0.760
2.5 0.2 2.2 PI-E 0.338; 0.601
2.5 0.1 2.2 E-FM 0.287; 0.609
2.3 0.2 2.2 PI-FM 0.411; 0.502
2.5 0.1 2.1 PI-E 0.365; 0.553
2.5 0.1 2.3 E-FM 0.487; 0.389
3.8 0.0 3.4 PI-FM 0.772; 0.446
3.7 0.1 2.8 PI-E 0.677; 0.548
3.5 0.2 2.6 E-FM 0.683; 0.485ex (
wee
1
1
1after felodipine metoprolol, 12/9 mm Hg after enalapril,
19
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nificantly greater in both active treatment groups than in
the placebo group. The BP reduction was also significantly
greater in the felodipine  metoprolol group than in the
enalapril group (mean difference 6/5 mm Hg; P  .001).
The proportion of responders after 12 weeks (ie, patients
with diastolic BP 90 mm Hg or a reduction in diastolic
BP 10 mm Hg) were 82%, 57%, and 46% in the felo-
dipine  metoprolol, enalapril, and placebo groups, re-
spectively.
Discussion
This double-blind, placebo-controlled study shows that
HRQL is maintained in the presence of substantial BP
reduction during antihypertensive treatment with felodip-
ine  metoprolol combination tablets.
The study population was recruited from general prac-
tices in Europe and Canada and consisted of more than
900 men and women, aged 20 to 70 years, with mild-to-
moderate primary hypertension. Thus, the patients studied
can be regarded as representative for the ordinary white
hypertensive patient.
The PGWB and the SSA-P were selected for the as-
sessment of HRQL on the basis of being well recognized
Table 3. Subjective Symptoms Assessment Profile
symptoms)
n
Baseline 12-w
Mean SD Mean
Emotional distress
Placebo 247 26.1 18.7 25.1
Enalapril 287 24.5 18.7 23.5
Felodipine–Metoprolol 293 24.4 17.8 24.1
G-1 Symptoms
Placebo 247 15.7 12.4 13.7
Enalapril 287 14.7 13.4 13.4
Felodipine–Metoprolol 295 12.0 9.6 13.9
Peripheral circulatory
symptoms
Placebo 247 16.2 15.3 15.9
Enalapril 287 16.1 13.7 16.0
Felodipine–Metoprolol 296 14.9 12.8 17.3
Cardiac symptoms
Placebo 246 16.1 16.4 14.0
Enalapril 287 14.4 15.1 12.6
Felodipine–Metoprolol 295 13.2 15.1 12.4
Sexual life
Placebo 237 32.1 21.3 35.0
Enalapril 274 30.7 20.1 32.4
Felodipine–Metoprolol 281 35.5 22.3 35.0
Dizziness
Placebo 245 17.9 20.3 15.7
Enalapril 287 17.6 18.8 16.5
Felodipine–Metoprolol 292 15.8 18.7 17.1and validated.9 The large number of patients in this studyensured high statistical power to detect also small differ-
ences between study treatments in effects on HRQL. In
fact, a retrospective power analysis confirmed that the
study had 92% power to detect a difference of 3.5 units in
PGWB total score.
More patients were discontinued in the placebo group
(n  52) than in the felodipine  metoprolol group (n 
21) or the enalapril group (n  29). The most common
reasons were too high BP in the placebo and enalapril
groups, and adverse events in the felodipine  metoprolol
group. It is unlikely that these differences in discontinua-
tion rates between the treatment groups have introduced
any serious bias in the analysis of the study and caused
erroneous conclusions. First, the number of patients dis-
continued was low in relation to all patients in each
treatment group. Second, exclusion of more patients with
too high BP in the placebo group leads to the BP-lowering
effect of active treatments being underestimated. Third,
patients who were discontinued because of too high BP
most likely had low rather than high HRQL, and exclusion
of more such patients in the placebo group results in their
HRQL being overestimated.
The patients’ HRQL was generally high at baseline.
The mean PGWB total scores of 104 indicate high general
well-being, and are similar to those previously observed in
A-P) dimensions (the lower the value the less
k
Difference
12-week 
Baseline
Comparison 98.3% CID Mean SD
.6 1.1 16.0 PI-FM 3.973; 2.209
.7 0.9 14.6 PI-E 3.360; 2.845
.1 0.3 14.4 E-FM 3.591; 2.341
.9 2.0 10.8 PI-FM 5.908; 1.715
.8 1.4 10.1 PI-E 2.711; 1.506
.3 1.8 9.5 E-FM 5.221; 1.197
.0 0.2 15.5 PI-FM 5.540; 0.176
.8 0.1 12.2 PI-E 3.059; 2.693
.3 2.4 14.0 E-FM 5.241; 0.243
.8 2.1 15.3 PI-FM 4.431; 1.698
.4 1.8 14.0 PI-E 3.440; 2.724
.1 0.7 15.3 E-FM 3.946; 1.929
.2 2.9 22.0 PI-FM 1.103; 7.786
.8 1.7 21.1 PI-E 3.382; 5.553
.7 0.5 19.7 E-FM 2.013; 6.525
.3 2.3 18.3 PI-FM 7.351; 0.590
.3 1.1 19.0 PI-E 5.107; 2.856
.6 1.2 19.9 E-FM 6.057; 1.546(SS
ee
S
18
17
18
10
10
10
15
13
15
13
13
13
24
22
22
18
18a general population sample.13 In addition, the mean
1318 AJH–October 2005–VOL. 18, NO. 10FELODIPINE–METOPROLOL COMBINATION TABLET AND QUALITY OF LIFESSA-P scores were generally low, and few mean values
were above 20 on the 0 to 100 scale. Thus, most patients
had no or only mild symptoms. The high HRQL at base-
line observed in this study is in agreement with findings in
other studies of hypertensive patients14 and supports pre-
vious statements that hypertensive patients constitute an
asymptomatic population.
The mean PGWB and SSA-P scores were generally well
maintained during the study in all three treatment groups (ie,
HRQL was not negatively affected by treatment). The only
significant difference between treatments in the present study
was the slight increase in the SSA-P dimension “gastrointes-
tinal symptoms” during felodipine  metoprolol treatment
that differed from the slight decreases during enalapril or
placebo treatment. The occurrence of expected class-specific
side effects in some patients (eg, swollen ankles with felo-
dipine metoprolol and cough with enalapril) did not influ-
ence the general well-being in most patients, as there was no
decrease in mean PGWB scores. These symptoms were mild
or moderate in the majority of patients and caused few
discontinuations.
A number of previous comparative studies have shown
only small, if any, changes in HRQL during treatment with
calcium antagonists, -blockers, or angiotensin-convert-
ing enzyme (ACE) inhibitors.6,14–22 However, these stud-
ies did not exclude an effect on HRQL of the studied
drugs, as they were not placebo controlled.
Health-related quality of life was as well maintained
during treatment with felodipine  metoprolol as with
enalapril or placebo in spite of a considerably greater BP
reduction with felodipine  metoprolol. Thus, there
should be no concern that effective BP reduction with
felodipine  metoprolol would compromise HRQL. In
this context, it is notable that HRQL may even be posi-
tively related to BP reduction, as indicated in the Hyper-
tension Optimal Treatment study.23 It may be argued that
HRQL should preferably be measured at similar BP re-
duction in studies comparing different drugs to assess
possible differences in HRQL between treatments.6 How-
ever, the aim of this study was to test the assumption that
felodipine  metoprolol combination tablets reduce BP
substantially without compromising HRQL, and not to
compare HRQL at similar BP reductions.
In conclusion, this double-blind, placebo-controlled
study shows that HRQL is maintained in the presence of
substantial BP reduction during antihypertensive treatment
with felodipine  metoprolol fixed combination tablets.
The comparison with enalapril monotherapy supports cur-
rent recommendations that initiating therapy with combi-
nation treatment may be considered in patients who need
considerable BP reduction.
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